Abstract: This invention provides methods for specifically testing ulcerative colitis and primary sclerosing cholangitis. The first aspect of the invention provides a method for testing ulcerative colitis comprising a step of detection comprising detecting, as an indicator of ulcerative colitis, an antibody immunologically reacting with integrin ?V?6 and/or an antibody immunologically reacting with integrin ?V?3 in a specimen. The second aspect of the invention provides a method for testing primary sclerosing cholangitis comprising a step of detection comprising detecting, as an indicator of primary sclerosing cholangitis, an antibody immunologically reacting with integrin ?V?6 and/or an antibody immunologically reacting with integrin ?V?3 in a specimen.

Abstract: Provided is a cancer development risk assessment device (1) capable of determining the possibility of cancer development in a subject to be assessed in short time. The cancer development risk assessment device (1) includes a measurement unit (3) and a controller (4). The measurement unit (3) is configured to measure concentrations of a plurality of types of target components included in exhaled air collected from a subject to be assessed. The controller (4) is configured to calculate an assessment score correlated to the possibility of cancer being developed in the subject to be assessed based on measurement results of the concentrations obtained by the measurement unit (3).

Abstract: The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of HGF including measuring the amount of ?-fetoprotein (liver regeneration biomarker) and/or soluble Fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with HGF.

Abstract: The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of HGF including measuring the amount of ?-fetoprotein (liver regeneration biomarker) and/or soluble Fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with HGF.

Abstract: The present invention provides a therapeutic agent for treating inflammatory bowel diseases comprising as an active ingredient at least one member selected from polypeptides belonging a family exhibiting thioredoxin activity.

Abstract: The present invention provides a therapeutic agent for treating inflammatory bowel diseases comprising as an active ingredient at least one member selected from polypeptides belonging a family exhibiting thioredoxin activity.

Abstract: A method assists a semiconductor device developer to place an order for manufacturing a semiconductor device to specialized makers of different categories. The method asks a first maker to clarify a category of semiconductor device manufacture to which the first maker belongs. The method asks the first maker to select makers of other categories of semiconductor device manufacture with which the first maker wants to be interfaced. The method asks the makers concerned to fabricate a sample semiconductor device to confirm interfaces among the makers, and if the interfaces are confirmed, registers the makers as an interfaced maker group. The method asks the semiconductor device developer to enter the specifications of a semiconductor device developed by the developer. According to the specifications, the method retrieves maker groups and proposes to the developer the retrieved maker groups as proper maker groups capable of manufacturing the semiconductor device developed by the developer.

Abstract: Disclosed herein is a Japanese pear tree which has a moderate vigor and an easily maintained moderate spur development, is resistant to black spot disease, and as productive as `Hosui`. The tree is cross-incompatible with `Kosui` and is assumed to have an S.sub.4 S.sub.5 genotype, and has brown young leaves and white large flowers which have a pale red color at the pit at fat bud and bloom middle to late in the season and at almost the same time as `Nijisseiki`. The tree can produce an oblate-shaped fruit which matures early in the season, earlier than `Nijisseiki`, and has a normal keeping quality. The fruit has a large size which is larger than that of `Nijisseiki`, a skin which is covered partly with russet when cultivated without bagging, is at early maturity of the yellowish green color identified in the Munsel.RTM. Book of Color as follows:Hue symbol: 2.5 gyChroma: 6Value: 9,and is at full maturity of the yellow color identified in the Munsel.RTM.